At FDA, Graham is still the whistle-blower – USA Today Thu, 17 Nov 2005 On Nov. 18, 2004, Dr. David Graham, FDA’s associate director for science and medicine, blew the whistle in testimony before the Senate Finance Committee, on FDA’s “profound regulatory failure” to protect the public against lethal prescription…
Rutherford Institute Interview: Allen Jones reveals TMAP drug scam linked to then Governor George W. Bush Fri, 14 Oct 2005 An in-depth interview by John Whitehead of the Rutherford Institute with Allen Jones,*a former inspector with the Pennsyvania Office of Inspector General, who initially blew the whistle on Pennsylvania’s version…
APA Under the Influence of PhaRma June 5, 2002 FYI Reporters who attended the 2002 annual convention of the American Association of Psychiatry / PhaRma have had a rude awakening about the scope of industry’s influence. Essentially, psychiatrists are drug marketers for industry, helping to create blockbuster sales: Â Even…
$95 billion a year spent on medical research in US – JAMA Fri, 23 Sep 2005 A special issue of the Journal of the American Medical Association, JAMA, focuses on medical research spending and findings. A study that examined US spending for medical research—$95 billion approaching $100 billion–57% is spent…
SAMHSA Backs Away From TeenScreen & TMAP Mon, 24 Oct 2005 On October 17, a meeting took place with Charles Currie in Washington DC – with some in attendance by conference call. Currie is the Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA), the federal agency charged…
Schizophrenia drugs increase diabetes risk Fri, 29 Aug 2003 A large scale study by the Veterans Administration corroborates a body of evidence demonstrating that the much touted “improved” newer drugs for the treatment of schizophrenia–Zyprexa, Risperdal, Seroquesl– are precipitating the onset of diabetes at alarming rates– especially among younger patients….
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
The most striking acknowledgement in this sad story underscores the shaky foundation upon which the field of child psychiatry rests is the following statement by a Harvard University child psychiatrist: "When she was almost 8… Haley met full criteria for virtually every mental disorder listed."
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
